Skip to main content

Advertisement

SpringerLink
Log in

FANCD2 mRNA Overexpression is a Bona Fide Indicator of Lymph Node Metastasis in Human Colorectal Cancer

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Lymph node metastasis is widely accepted as one of the most important determinants of prognosis in colorectal cancer (CRC) patients. Therefore, there is an urgent need to identify molecular markers that can be used to predict lymph node metastasis.

Materials and Methods

Candidate genes were found using LMD and cDNA microarrays in a large-scale study of CRC, followed by Penalized Canonical Correlation Analysis (PCCA). We focused on the Fanconi anemia, complementation group D2 (FANCD2) gene and evaluated FANCD2 mRNA expression in 133 CRC cases to determine the clinicopathological significance of FANCD2 expression.

Results

The mean level of FANCD2 mRNA expression in tumor tissue specimens was significantly higher than in nontumor tissue. FANCD2 expression was found to be a significant factor affecting lymph node metastasis: the high FANCD2 expression group had a significantly poorer prognosis than the low expression group.

Conclusions

This study suggests that PCCA can be used to identify genes related to clinicopathological features. Furthermore, high FANCD2 expression was a significant independent factor for lymph node metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–6.

    Article  PubMed  Google Scholar 

  2. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–47.

    CAS  PubMed  Google Scholar 

  3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.

    Article  PubMed  Google Scholar 

  4. Newland RC, Chapuis PH, Pheils MT, MacPherson JG. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer. 1981;47:1424–9.

    Article  CAS  PubMed  Google Scholar 

  5. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;12:3057–63.

    Article  CAS  PubMed  Google Scholar 

  6. Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M. Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. Int J Oncol. 2007;31:333–8.

    CAS  PubMed  Google Scholar 

  7. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249–56.

    Article  CAS  PubMed  Google Scholar 

  8. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822–6.

    Article  CAS  PubMed  Google Scholar 

  9. Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003;17:2021–35.

    Article  CAS  PubMed  Google Scholar 

  10. van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2008;107:41–7.

    Article  PubMed  Google Scholar 

  11. Nishida K, Mine S, Utsunomiya T, Inoue H, Okamoto M, Udagawa H, et al. Global analysis of altered gene expressions during the process of esophageal squamous cell carcinogenesis in the rat: a study combined with a laser microdissection and a cDNA microarray. Cancer Res. 2005;65:401–9.

    CAS  PubMed  Google Scholar 

  12. Quackenbush J. Microarray data normalization and transformation. Nat Genet. 2002;32 Suppl:496–501.

    Article  CAS  PubMed  Google Scholar 

  13. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365–71.

    Article  CAS  PubMed  Google Scholar 

  14. Waaijenborg S, Verselewel de Witt Hamer PC, Zwinderman AH. Quantifying the association between gene expressions and DNA-markers by penalized canonical correlation analysis. Stat Appl Genet Mol Biol. 2008;7:Article3.

  15. Waaijenborg S, Zwinderman AH. Penalized canonical correlation analysis to quantify the association between gene expression and DNA markers. BMC Proc. 2007;1Suppl1:S122.

    Article  PubMed  Google Scholar 

  16. Razavi AR, Gill H, Stal O, Sundquist M, Thorstenson S, Ahlfeldt H, et al. Exploring cancer register data to find risk factors for recurrence of breast cancer—application of Canonical Correlation Analysis. BMC Med Inform Decis Mak. 2005;5:29.

    Article  PubMed  Google Scholar 

  17. Utsunomiya T, Hara Y, Kataoka A, Morita M, Arakawa H, Mori M, et al. Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res. 2002;8:2591–4.

    CAS  PubMed  Google Scholar 

  18. Utsunomiya T, Okamoto M, Hashimoto M, Yoshinaga K, Shiraishi T, Tanaka F, et al. A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. J Hepatol. 2004;41:399–406.

    Article  CAS  PubMed  Google Scholar 

  19. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005;11:2889–93.

    Article  CAS  PubMed  Google Scholar 

  20. D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23–34.

    Article  PubMed  Google Scholar 

  21. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7:249–62.

    Article  CAS  PubMed  Google Scholar 

  22. Holzel M, van Diest PJ, Bier P, Wallisch M, Hoatlin ME, Joenje H, et al. FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia. J Pathol. 2003;201:198–203.

    Article  CAS  PubMed  Google Scholar 

  23. Houghtaling S, Granville L, Akkari Y, Torimaru Y, Olson S, Finegold M, et al. Heterozygosity for p53 (Trp53 ±) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res. 2005;65:85–91.

    CAS  PubMed  Google Scholar 

  24. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.

    Article  CAS  PubMed  Google Scholar 

  25. Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 2006;130:2145–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We thank S. Waaijenborg for kindly providing the PCCA software. We also thank Dr. Yoshikawa, Dr. Ohishi, Ms. T Shimooka, Mrs. K Ogata, Ms. M Kasagi, Ms. Y Nakagawa, and MsT Kawano for their excellent advice and technical assistance. This work was supported in part by the following grants and foundations: Core Research for Evolutional Science and Technology, Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare No. 17-15, and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, No. 20790960 and 19390336.

Author information

Authors and Affiliations

  1. Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan

    Heita Ozawa MD & Masahiko Watanabe MD

  2. Department of Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan

    Masaaki Iwatsuki MD, Koshi Mimori MD & Masaki Mori MD, FACS

  3. Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

    Tetsuya Sato PhD, Fredrik Johansson PhD & Hiroyuki Toh PhD

Authors
  1. Heita Ozawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Iwatsuki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koshi Mimori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuya Sato PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fredrik Johansson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Toh PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiko Watanabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaki Mori MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Mori MD, FACS.

Additional information

Heita Ozawa and Masaaki Iwatsuki contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozawa, H., Iwatsuki, M., Mimori, K. et al. FANCD2 mRNA Overexpression is a Bona Fide Indicator of Lymph Node Metastasis in Human Colorectal Cancer. Ann Surg Oncol 17, 2341–2348 (2010). https://doi.org/10.1245/s10434-010-1002-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1002-7

Keywords

Search

Navigation